Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“Join me and my esteemed colleagues for a discussion on the emerging biomarkers of HER2 low and ultra-low, a deep dive into Destiny Breast 04 and 06 data, optimal positioning of T-DXd, and most importantly patient selection and toxicity management considerations.”
Sarah Sammons previewed an upcoming expert discussion focused on HER2 low and ultra-low biomarkers, recent Destiny Breast clinical trial data, and strategies for effective use of T-DXd including patient selection and toxicity management.
More posts featuring Sarah Sammons.